Table 3

DHFRa, RFCa, TSb, E2F-1c, and E2F-4b expression values in OS patient samples

DHFR
RFC
TS
E2F-1
E2F-4
RangeMedianRangeMedianRangeMedianRangeMedianRangeMedian
Total samples (n = 112)0.02–33.130.20.02–229.131.910.01–9.990.150.05–69.070.520.24–52.35(n = 107)1.45
Primary site(n = 90)0.02–33.130.20.02–229.131.770.02–9.990.160.05–69.070.520.24–52.35(n = 86)1.61
Metastatic site (n = 22)0.03–0.700.190.20–21.112.550.01–1.130.140.06–8.400.510.24–4.56(n = 21)1.82
Huvos I and II (n = 43)0.03–22.780.280.14–125.372.50.02–9.990.20.08–69.070.670.24–18.641.78
Huvos III and IV (n = 26)0.02–33.130.180.03–229.131.70.02–6.190.120.07–37.790.470.24–52.351.61
  • a Values are relative to the CCRF-CEM-positive control cell line.

  • b Values are relative to the HOS-positive control cell line.

  • c Values are relative to the SkBr3-positive control cell line.